April 2022 - A major study elucidating the mechanism of action of the IBD-asset has been completed: Alma's treatment facilitates mucosal healing without immune suppression
March 2022 - WO 2022/070052 A1, a new PCT covering the effect of our IBD-asset on gut dysbiosis and impaired barrier function, was published online.
February 2022 - Alma attended ECCO 2022, the 17th congress of European Crohn's and Colitis Organisation
March 2021 - Alma Bio Therapeutics presented in the biotech session of the special webinar “Bouncing back from the crisis. How to re-establish partnerships between Israel and the Auvergne Rhône-Alpes…
January 2021 – Alma Bio Therapeutics attended the 4th Antigen Specific Immune Tolerance digital event.